DeepMed Research

EPIGENOMICS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CRC Detection Reliable Assessment With Blood

Active, not recruiting

Conditions: Adenomas Colon
Rectal Diseases
Colon Cancer
Rectal Polyp
Colon Neoplasm
Colon Polyp
Gastrointestinal Neoplasms
Colonic Diseases, Functional
Intestinal Disease
Colorectal Cancer

Interventions: Diagnostic Test: Next-Gen CRC Screening Test

First Posted Date: 2022-09-22

Last Posted Date: 2023-05-23

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 196

Registration Number: NCT05551052

Locations: 🇺🇸
Medical Associates Research Group, San Diego, California, United States
🇺🇸
SDG Clinical Research, San Diego, California, United States
🇺🇸
Gastro SB, Chula Vista, California, United States

Plasma-based Colorectal Cancer Screening Research & Development

Completed

Conditions: Colo-rectal Cancer

Interventions: Diagnostic Test: Epi proColon

First Posted Date: 2019-07-22

Last Posted Date: 2021-02-02

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 354

Registration Number: NCT04027790

Locations: 🇺🇸
Springfield Clinic, Springfield, Illinois, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

and more 2 locations

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

Completed

Conditions: Cirrhosis, Liver
Hepatic Cirrhosis
Hepatocellular Carcinoma
Liver Cancer

First Posted Date: 2019-01-15

Last Posted Date: 2020-01-30

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 175

Registration Number: NCT03804593

Locations: 🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇺🇸
USC Keck Medical Center, Los Angeles, California, United States

Longitudinal Performance of Epi proColon

Conditions: Colorectal Neoplasms
Colorectal Cancer

First Posted Date: 2017-07-14

Last Posted Date: 2021-11-01

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 4500

Registration Number: NCT03218423

Locations: 🇺🇸
Geisinger Health System, Danville, Pennsylvania, United States
🇺🇸
Rutgers University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Beaumont Health System, Royal Oak, Michigan, United States

and more 3 locations

Adherence to Minimally Invasive Testing

Completed

Conditions: Colorectal Cancer

Interventions: Device: Fecal Immunochemical Test (FIT)
Device: Epi proColon Test

First Posted Date: 2014-09-29

Last Posted Date: 2015-06-30

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 490

Registration Number: NCT02251782

Locations: 🇺🇸
Kaiser Permanente Center for Health Research, Portland, Oregon, United States
🇺🇸
Geisinger Clinic, Danville, Pennsylvania, United States

Head to Head Study Epi proColon and FIT

Completed

Conditions: Colorectal Cancer

First Posted Date: 2012-04-19

Last Posted Date: 2015-08-04

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 336

Registration Number: NCT01580540

Locations: 🇵🇷
Clinical Research of Puerto Rico, San Juan, Puerto Rico
🇺🇸
PMI Research, Atlanta, Georgia, United States
🇺🇸
Palm Springs Research Institute, Inc, Miami, Florida, United States

and more 67 locations

Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test

Withdrawn

Conditions: Colorectal Cancer

First Posted Date: 2012-04-10

Last Posted Date: 2014-08-04

Lead Sponsor: Epigenomics, Inc

Registration Number: NCT01574677

Locations: 🇺🇸
Kaiser Permanente Northwest, Portland, Oregon, United States
🇺🇸
Kaiser Permanente Georgia, Atlanta, Georgia, United States

Specimens for Septin 9 Performance

Early Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Other: Blood Sample

First Posted Date: 2011-04-06

Last Posted Date: 2014-08-04

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 562

Registration Number: NCT01329718

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

Completed

Conditions: Colorectal Cancer

Interventions: Other: All eligible subjects will provide blood for SEPT9 biomarker testing

First Posted Date: 2009-03-04

Last Posted Date: 2014-08-04

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 7929

Registration Number: NCT00855348

Locations: 🇺🇸
GI Care Center, Miami, Florida, United States
🇺🇸
Digestive Care, Boca Raton, Florida, United States
🇺🇸
Charlottesville Medical Research, Charlottesville, Virginia, United States

and more 20 locations

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

Completed

Conditions: Colorectal Cancer

First Posted Date: 2008-06-12

Last Posted Date: 2008-06-17

Lead Sponsor: Epigenomics, Inc

Target Recruit Count: 700

Registration Number: NCT00696345

Locations: 🇩🇪
Department of Visceral-, Thoracic- and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany
🇩🇪
Department of Surgery and Surgical Oncology, Charité Campus Berlin Buch, Berlin, Germany
🇩🇪
Department of Surgery, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy